Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humansInterventional

A Study of EOS006215 in Adult Participants with Advanced Solid Tumors

This is an early-stage research study looking at a new medicine called EOS006215. It's designed for adult patients who have solid cancers that are advanced. The main goal of this particular study is to see how safe the new medicine is and how the body handles it, as this is the very first time it's being given to people. Researchers will also be looking for early signs of whether it might be effective against cancer. Because it's such an early study, there isn't much information yet, but it's an important step in developing new treatments for advanced solid tumours. It's open to adults aged 18 and over, both men and women.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

iTeos Belgium

Enrolment target

Start

01 Apr 2025

Solid Tumors

What is this study about?

This research is looking into a brand-new medicine called EOS006215. It's for adults who have solid cancers that have spread or are difficult to treat. Solid cancers are those that form a lump or tumour, like breast, lung, or bowel cancer, rather than blood cancers like leukaemia.

This is a very early study, which doctors call a 'Phase I' trial. This means it's the first time this specific medicine is being given to people. The main aim is to understand if it's safe, what dose works best, and how it behaves in the body. Researchers also hope to get an early idea of whether it might help to treat these advanced cancers.

Developing new cancer treatments is a long process, and studies like this are a crucial first step. While it's too early to know if this medicine will be a widely used treatment, trials like this help scientists learn more and potentially lead to new options for patients in the future.

Key takeaways

This is an early study of a new medicine (EOS006215) for advanced solid cancers.
The main goal is to check safety and how the medicine works in the body.
It's for adults aged 18 and over with solid tumours.
Patients get access to a new treatment, but potential side effects are still being learned.
Participation involves regular hospital visits for monitoring.

Who may be eligible?

This study is open to adults who are 18 years old or older. Both men and women can take part.

Because this is an early-stage study for advanced solid cancers, there will be very specific health requirements. For example, your cancer must be a 'solid tumour' (not a blood cancer) and be at an advanced stage. You will also need to be fit enough to take part in the study and potentially tolerate the new medicine.

Before you can join, the study doctors will need to carefully check your medical history, recent test results, and overall health to make sure the study is a suitable and as safe as possible for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of advanced solid cancer?
Are you able to travel to a study clinic for regular appointments?
Are you comfortable with receiving a new, untested medicine?
Are you willing to have frequent medical tests and monitoring?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would receive the new medicine, EOS006215. The study team would closely monitor your health with regular check-ups, blood tests, and scans. You would have frequent visits to the hospital or clinic, especially in the beginning, to ensure your safety and see how the medicine is affecting you.

The total duration of your involvement could vary. You would likely take the medicine for a period, followed by regular follow-up appointments to track your progress and any side effects. All of your appointments, tests, and the study medicine would be provided by the trial.

Potential risks and benefits

Patients who take part in early-stage studies like this might benefit from gaining access to a new medicine that isn't yet widely available. While we don't know if this particular medicine will help, there's a chance it could have a positive effect for some people. However, because it's a new medicine, there could be side effects that are not yet fully known. The research team will carefully monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What kind of cancer is this study for?

This study is for adults with advanced solid tumours, which are cancers that form a lump rather than blood cancers.

What does 'Phase I' mean?

Phase I means it's a very early study, and it's the first time this new medicine is being given to people, mainly to check its safety and how it works in the body.

Who can join this study?

Adults aged 18 and over, both men and women, with advanced solid tumours may be able to join, depending on other health checks.

Will I get paid to join?

Clinical trials in the UK typically don't pay you to participate, but often reimburse travel expenses and other costs related to your visits.

Can I stop taking part if I change my mind?

Yes, you can leave the study at any time, for any reason, without affecting your medical treatment or relationship with your healthcare team.